End-of-day quote
Shanghai S.E.
23:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
1.76
CNY
|
+0.57%
|
|
-2.76%
|
-5.38%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
45,809
|
18,553
|
13,330
|
42,839
|
30,501
|
25,787
|
Enterprise Value (EV)
1 |
79,760
|
50,466
|
43,843
|
40,626
|
29,257
|
24,985
|
P/E ratio
|
50.3
x
|
-3.77
x
|
-0.48
x
|
5.42
x
|
-11.6
x
|
186
x
|
Yield
|
0.26%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.37
x
|
1.62
x
|
2.46
x
|
10.3
x
|
7.3
x
|
5.29
x
|
EV / Revenue
|
4.12
x
|
4.41
x
|
8.1
x
|
9.78
x
|
7
x
|
5.13
x
|
EV / EBITDA
|
22.4
x
|
-48.8
x
|
-1.92
x
|
-16.2
x
|
-39.7
x
|
50.9
x
|
EV / FCF
|
-12
x
|
11
x
|
4.03
x
|
-6.74
x
|
250
x
|
-89.9
x
|
FCF Yield
|
-8.34%
|
9.08%
|
24.8%
|
-14.8%
|
0.4%
|
-1.11%
|
Price to Book
|
1.82
x
|
1.06
x
|
-1.31
x
|
4.32
x
|
4.39
x
|
3.66
x
|
Nbr of stocks (in thousands)
|
4,973,862
|
4,973,862
|
4,973,862
|
13,863,867
|
13,863,867
|
13,863,867
|
Reference price
2 |
9.210
|
3.730
|
2.680
|
3.090
|
2.200
|
1.860
|
Announcement Date
|
30/04/19
|
17/06/20
|
28/04/21
|
28/04/22
|
28/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
19,356
|
11,446
|
5,411
|
4,153
|
4,180
|
4,874
|
EBITDA
1 |
3,553
|
-1,033
|
-22,851
|
-2,512
|
-736.3
|
491
|
EBIT
1 |
3,056
|
-1,704
|
-23,456
|
-3,046
|
-1,040
|
205.4
|
Operating Margin
|
15.79%
|
-14.89%
|
-433.45%
|
-73.37%
|
-24.89%
|
4.21%
|
Earnings before Tax (EBT)
1 |
1,362
|
-4,391
|
-27,685
|
8,155
|
-2,664
|
110.4
|
Net income
1 |
1,135
|
-4,661
|
-27,736
|
7,918
|
-2,689
|
102.5
|
Net margin
|
5.86%
|
-40.72%
|
-512.54%
|
190.68%
|
-64.32%
|
2.1%
|
EPS
2 |
0.1830
|
-0.9896
|
-5.616
|
0.5700
|
-0.1900
|
0.0100
|
Free Cash Flow
1 |
-6,648
|
4,585
|
10,876
|
-6,029
|
117.2
|
-278
|
FCF margin
|
-34.35%
|
40.06%
|
200.98%
|
-145.2%
|
2.8%
|
-5.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0240
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/04/19
|
17/06/20
|
28/04/21
|
28/04/22
|
28/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
33,951
|
31,913
|
30,513
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
2,214
|
1,244
|
802
|
Leverage (Debt/EBITDA)
|
9.555
x
|
-30.88
x
|
-1.335
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6,648
|
4,585
|
10,876
|
-6,029
|
117
|
-278
|
ROE (net income / shareholders' equity)
|
3.95%
|
-19.9%
|
-408%
|
-3,591%
|
-31.8%
|
1.47%
|
ROA (Net income/ Total Assets)
|
2.73%
|
-1.55%
|
-29.1%
|
-7.71%
|
-4.17%
|
0.87%
|
Assets
1 |
41,584
|
301,311
|
95,352
|
-102,673
|
64,438
|
11,762
|
Book Value Per Share
2 |
5.070
|
3.530
|
-2.040
|
0.7200
|
0.5000
|
0.5100
|
Cash Flow per Share
2 |
0.3700
|
0.1000
|
0.1100
|
0.1700
|
0.1100
|
0.0800
|
Capex
1 |
4,593
|
473
|
302
|
172
|
48.1
|
99.7
|
Capex / Sales
|
23.73%
|
4.13%
|
5.58%
|
4.13%
|
1.15%
|
2.05%
|
Announcement Date
|
30/04/19
|
17/06/20
|
28/04/21
|
28/04/22
|
28/04/23
|
12/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -5.38% | 3.34B | | +54.61% | 815B | | +44.25% | 654B | | -6.33% | 354B | | +20.62% | 337B | | +10.44% | 302B | | +18.45% | 247B | | +2.09% | 229B | | +13.03% | 219B | | +8.61% | 171B |
Other Pharmaceuticals
|